Does Wegovy Lower Blood Pressure? What Clinical Trials Found

What the trial data actually recorded on blood pressure

The STEP 1 trial, published in the New England Journal of Medicine, followed 1,961 adults with obesity over 68 weeks. Participants on semaglutide 2.4mg saw average systolic blood pressure fall by around 6 mmHg more than those on placebo. Diastolic pressure also fell, though by a smaller margin. These are group averages, so individual results vary, but the direction was consistent across the STEP programme broadly.

More striking is the SELECT trial, which enrolled adults who already had established cardiovascular disease. Over a median of around three years, semaglutide reduced the risk of a major cardiovascular event (heart attack, stroke or cardiovascular death) by roughly 20% compared with placebo. That trial didn't select for high blood pressure specifically, yet blood-pressure improvements were part of the picture with Wegovy. The NHS medicines information for semaglutide notes that cardiovascular risk reduction is now part of the medicine's UK authorised indications for certain patients, reflecting how seriously regulators take this evidence.

A few caveats worth holding onto: blood pressure figures in trials represent populations, not individuals. Someone whose pressure is already well-controlled may see a smaller shift. Someone with significant hypertension alongside obesity may see a larger one. The data justify optimism, not certainty.

Why semaglutide may lower blood pressure beyond simply losing weight

Weight loss itself reliably reduces blood pressure, roughly 1 mmHg per kilogram lost is a commonly cited rule of thumb in cardiovascular medicine. So part of the effect observed in STEP 1 will simply reflect lighter bodies placing less demand on the circulatory system. That's entirely real and clinically useful.

But researchers have noticed the blood-pressure reduction in semaglutide trials looks larger than weight loss alone would account for. GLP-1 receptors are found not just in the gut and brain but in the kidneys and blood vessel walls. Activation appears to promote natriuresis (sodium excretion via the kidneys) which reduces circulating fluid volume and, with it, pressure on arterial walls. There may also be a modest direct vasodilatory effect, though the science here is still being worked out.

If you want to understand how semaglutide works more broadly, the full mechanism is covered on the semaglutide overview page. For a side-by-side look at Wegovy specifically and what it does for cardiovascular health markers, the Wegovy and blood pressure detail page goes deeper into the monitoring side.

What this means for people already on blood pressure medication

This is probably the most practical question, and it deserves a plain answer: if you start semaglutide and your blood pressure falls meaningfully, your existing antihypertensive medication may become relatively too strong. That can cause its own problems. Lightheadedness on standing, dizziness after exercise, or unexpectedly low readings at home are worth taking seriously.

One useful habit, if you have a home blood pressure cuff: take a reading before your weekly injection and again a few days later during the first month or two of treatment. It takes under a minute and gives you real data to share with your prescriber or GP. If you are wondering whether Wegovy can genuinely help with blood pressure, a trend downward is worth flagging early with your prescriber.

Your prescriber should know about any antihypertensive medicines you take when they assess you. At nume, consultations are reviewed personally by a GPhC-registered Independent Prescriber, not by an automated triage system, so existing medications and cardiovascular history form part of the clinical picture from the start. Questions about ongoing monitoring can also be directed through our aftercare team, available seven days a week.

The broader point is that semaglutide's blood-pressure effects are a reason for optimism for many people, and also a reason to stay properly supervised. A medicine that's doing its job well can change what dose of another medicine you still need. That's a good problem to have, but it's one for a prescriber, not a trial statistic, to manage.

For context on what Wegovy treatment involves from a cost and access perspective, the Wegovy pricing page covers what private treatment typically includes. If you're considering starting, and particularly if you're exploring Dr Reddy's semaglutide as one of your options, the right first step is a clinical assessment where your blood pressure history, current medications and overall cardiovascular picture can be properly reviewed.

Ready to speak to our prescribers? Start your free consultation and get a same-day clinical review from a registered prescriber who will take your full health picture into account.